Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

US market

This page shows the latest US market news and features for those working in and with pharma, biotech and healthcare.

Servier to acquire Agios’ oncology business in $1.8bn deal

Servier to acquire Agios’ oncology business in $1.8bn deal

It is a key step for the Servier Group as it will significantly strengthen our position in the US and reinforce our R&D capabilities in oncology. ... Aside from strengthening its oncology portfolio, Servier’s acquisition of Agios will allow the company

Latest news

More from news
Approximately 1 fully matching, plus 823 partially matching documents found.

Latest Intelligence

  • Growing evidence supports the important role of biosimilars in healthcare Growing evidence supports the important role of biosimilars in healthcare

    Access to healthcare, including affordable medicines, remains a top concern across the US. ... As more biosimilars enter the US market, patients treated with biologic medicines will have access to a broader set of more affordable treatment options.

  • The US celebrates five years of biosimilars on the market – a look to the past, present and future The US celebrates five years of biosimilars on the market – a look to the past, present and future

    Yet unlike generic medicines, which have delivered substantial savings in the small molecule market, the success of biosimilars in the US has been mixed. ... Moreover, increasing the number of available biosimilars on the US market can improve access to

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    But for the most part, the feast-and-famine cycle of the US market has been viewed as a success. ... And finally there is the issue of interchangeability. In a move unique to the US market, the BPCI created two pathways for approval: an abbreviated one

  • The Golden Goose The Golden Goose

    The significance of the US market is also why Ehrlich, along with many others on the business/ marketing side of the industry, has little faith that importing cheaper drugs into the ... Drug-makers will not allow their golden goose US market to be

  • It’s not the end of the world, is it? It’s not the end of the world, is it?

    the US market when they would, de facto, be barred from other developed and price-controlled markets. ... It would have a disproportionate effect, for example, on companies who depend heavily on the US market.

More from intelligence
Approximately 0 fully matching, plus 52 partially matching documents found.

Latest appointments

  • New faces at 11 London, ramarketing and MSL New faces at 11 London, ramarketing and MSL

    The new office in Cambridge, Massachusetts, will give ramarketing a presence in the growing pharma and biotech hub and a foothold in the US market, allowing it to locally service its ... Emma’s insight into the global life sciences sector means she

  • Pharma industry appointments Pharma industry appointments

    Prior to this, Jenkins spent 17 years at GlaxoSmithKline (GSK) in the UK and US. ... UK. Vu, whose new post will see him further expand Concept’s presence in the US market, joins the company with over 15 years’ experience in both business development

  • Open Health creates new role Open Health creates new role

    Joining the agency with twenty years’ biopharmaceutical industry experience, Jones’ expertise lies in market access, therapy launch and patient centric services. ... Creating a unique role within our field of expertise will enable us to offer a

  • W2O bolsters its commercialisation offering W2O bolsters its commercialisation offering

    Rita Glaze joins the firm as leader of value, pricing and market access practice. ... Joining the network from Edelman, Glaze previously led the design and implementation of its US market access communications offering.

  • Amra appoints new VP of North American sales Jeremy Edwards Amra appoints new VP of North American sales Jeremy Edwards

    With more than 20 years’ experience in the clinical development industry, Edwards joins the company after spending five years as vice president and general manager of the US operations for Exco ... expand the US market.”.

More from appointments
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 45 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Quick links

Infographics

Multimedia